New pill for MS enters early human testing

NCT ID NCT07085507

Recruiting now Disease control Sponsor: Vidya Therapeutics Inc Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This early-phase trial is testing an oral drug called VT7208 in healthy volunteers and people with multiple sclerosis (MS). The study has three parts: first, checking safety and how the drug moves through the body in healthy adults; second, seeing how food affects the drug; and third, testing safety in MS patients. About 100 people will take part, and the goal is to see if VT7208 is safe enough for further study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VT7208 (an oral small molecule drug)
What this could lead to: If successful, this could point toward a new oral treatment option for multiple sclerosis that helps control the disease.
What could go wrong: This is a very early phase 1/2 trial with only 100 participants, so safety and effectiveness are not yet known. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

CMAX
RECRUITING

Adelaide, South Australia, 5000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.